26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
11 June 2019REVIVE webinar: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease researchIn this webinar, William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy, will introduce experimental…read more >>
05 June 2019Advancing Data Technologies to corner Antimicrobial ResistanceAntimicrobial resistance (AMR) already now is the largest global threat to Health and Food Safety (source: WHO). Without the focused…read more >>
03 June 2019BIO International ConventionThe key benefits of attending the 2019 BIO International Convention are access to global biotech and pharma leaders via BIO…read more >>
03 June 20196th World Congress and Exhibition on Antibiotics and Antibiotic ResistanceTheme: Challenges and New Concepts in Antibiotics Researchread more >>
23 May 2019Global Scale-up Program: Venture Scaling Strategy & PreparationVenture assessment and individual intake Scale-up Entrepreneurial Finance Scale-up Entrepreneurial Marketing & Global Strategyread more >>
22 May 2019NAPD Symposium ‘Accelerating antibiotic development in Europe’The Netherlands Antibiotic Development Platform (NADP) is organizing its second annual meeting, titled 'Accelerating antibiotic development in Europe'. The program…read more >>
21 May 2019GARDP webinar: Mining Chemical Libraries for New AntibacterialsDespite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has…read more >>
13 April 201929th ECCMIDESCMID's yearly congress attracts nearly 13'000 participants. ECCMID offers a wide range of sessions including: keynotes, symposia, poster sessions, educational…read more >>
28 March 2019GARDP webinar: Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional ProductsThe overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks…read more >>
